Tredje AP fonden Sells 4,679 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Tredje AP fonden lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,680 shares of the biotechnology company's stock after selling 4,679 shares during the quarter. Tredje AP fonden's holdings in United Therapeutics were worth $1,651,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics during the fourth quarter valued at $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the third quarter valued at about $33,000. MassMutual Private Wealth & Trust FSB raised its stake in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 258 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of United Therapeutics during the fourth quarter valued at about $131,000. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Price Performance

NASDAQ UTHR traded up $4.73 on Wednesday, hitting $318.85. 539,277 shares of the company were exchanged, compared to its average volume of 444,154. The company's 50 day moving average price is $348.15 and its 200-day moving average price is $357.92. The firm has a market capitalization of $14.32 billion, a P/E ratio of 14.00, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82.

Remove Ads

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the company earned $4.36 EPS. As a group, equities analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company's stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,255 shares of company stock valued at $32,614,521 in the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, HC Wainwright restated a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.